Aptevo Reports 10 of 47 Frontline AML Patients Advanced to Stem Cell Transplant
Aptevo said 10 of 47 evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine advanced to stem cell transplant.
Aptevo said 10 of 47 evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine advanced to stem cell transplant.